Rebecca J. Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca J. Daniels has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Christopher A. Knight
Department of Kinesiology and Applied Physiology, University of Delaware, Newark, USA
3 shared publications Christopher A. Knight
Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE, USA
2 shared publications- David Grenet
Department of Psychology, Concordia University, Montreal, Canada
1 shared publication Graham F. A. Harding
Clinical Neurophysiology Unit, Department of Vision Sciences, Aston University, Birmingham, UK
1 shared publicationNeville Drasdo
Clinical Neurophysiology Unit, Department of Vision Sciences, Aston University, Birmingham, UK
1 shared publicationSanjita Panchal
Clinical Neurophysiology Unit, Department of Vision Sciences, Aston University, Birmingham, UK
1 shared publication
Latest Publications
- 3 May 2026
- Published by Elsevier in Journal of Electromyography and Kinesiology
- Vol. 89, 103161
EMG analysis and correlates of motor segmentation in Parkinson’s disease
- 3 May 2026
- Published by Elsevier in Journal of Electromyography and Kinesiology
- Vol. 89, 103161
EMG analysis and correlates of motor segmentation in Parkinson’s disease
- Open Access
- 2 November 2025
- Published by Springer Nature in Experimental Brain Research
- Vol. 243 (12) , 1-15
Motor segmentation: a key neuromuscular impairment in people with parkinson’s disease
Healthy adults (OA) achieve rapid isometric force production with a brief, high amplitude burst of neural excitation. In some people with Parkinson’s disease (PwPD), transient reductions in neural excitation (motor segmentation) reduce rates of force development (RFD) and prolong contractions. Segmentation has strong relationships with time and rate-based measures of slowing in rapid contractions and is reliably measured from the second derivative of force (F”(t)). We sought more information about how segmentation affects neuromuscular control in PwPD. Aim 1 was to determine the prevalence of PwPD with segmentation (PD Seg ). Aim 2 was to determine how force performance differs in PD Seg , PwPD without segmentation (PD NoSeg ), and OA. Aim 3 was to quantify force segment durations. Fifty-seven PwPD ON medication and 22 OA performed rapid isometric finger abduction contractions to 20–60% of maximal voluntary contraction force. The median number of force segments to 90% of peak force were measured from F”(t) zero crossings. Additional outcomes included median times to peak force (tPF) and peak RFD (tRFD), and peak RFD (RFDpk). 68% of PwPD had segmentation (median segments ≥ 2, 95% CI [0.55 0.80]). PD Seg had slower tPF, tRFD and RFDpk than PD NoSeg and OA (all p ≤ 0.012, 0.38 ≤ r ≤ 0.85). PD NoSeg and OA did not have statistically different tPF, tRFD, or RFDpk ( p > 0.05). PD Seg had consistent segment durations (coefficient of variation ≤ 25.5%) and shorter first segment durations compared to PD NoSeg and OA ( p < 0.001, r ≥ 0.68), indicating PD Seg had reduced neuromuscular excitation prior to peak force. Segmentation identifies specific pathophysiology in neuromuscular control that exacerbates slowing in isometric force production.
- 2 November 2025
- Published by Springer Nature in Experimental Brain Research
- Vol. 243 (12) , 1-15
Open AccessMotor segmentation: a key neuromuscular impairment in people with parkinson’s disease
Healthy adults (OA) achieve rapid isometric force production with a brief, high amplitude burst of neural excitation. In some people with Parkinson’s disease (PwPD), transient reductions in neural excitation (motor segmentation) reduce rates of force development (RFD) and prolong contractions. Segmentation has strong relationships with time and rate-based measures of slowing in rapid contractions and is reliably measured from the second derivative of force (F”(t)). We sought more information about how segmentation affects neuromuscular control in PwPD. Aim 1 was to determine the prevalence of PwPD with segmentation (PD Seg ). Aim 2 was to determine how force performance differs in PD Seg , PwPD without segmentation (PD NoSeg ), and OA. Aim 3 was to quantify force segment durations. Fifty-seven PwPD ON medication and 22 OA performed rapid isometric finger abduction contractions to 20–60% of maximal voluntary contraction force. The median number of force segments to 90% of peak force were measured from F”(t) zero crossings. Additional outcomes included median times to peak force (tPF) and peak RFD (tRFD), and peak RFD (RFDpk). 68% of PwPD had segmentation (median segments ≥ 2, 95% CI [0.55 0.80]). PD Seg had slower tPF, tRFD and RFDpk than PD NoSeg and OA (all p ≤ 0.012, 0.38 ≤ r ≤ 0.85). PD NoSeg and OA did not have statistically different tPF, tRFD, or RFDpk ( p > 0.05). PD Seg had consistent segment durations (coefficient of variation ≤ 25.5%) and shorter first segment durations compared to PD NoSeg and OA ( p < 0.001, r ≥ 0.68), indicating PD Seg had reduced neuromuscular excitation prior to peak force. Segmentation identifies specific pathophysiology in neuromuscular control that exacerbates slowing in isometric force production.
- 1 October 2024
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 56 (10S) , 1007-1008
Variability In Rapid Force Production Predicts Motor Symptom Severity In Parkinson’s Disease
- 1 October 2024
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 56 (10S) , 1007-1008
Variability In Rapid Force Production Predicts Motor Symptom Severity In Parkinson’s Disease
- 19 March 2024
- Published by Elsevier in Human Movement Science
- Vol. 95, 103201
Impaired performance of rapid grip in people with Parkinson's disease and motor segmentation
- 19 March 2024
- Published by Elsevier in Human Movement Science
- Vol. 95, 103201
Impaired performance of rapid grip in people with Parkinson's disease and motor segmentation
- 1 December 2021
- Published by Elsevier in Clinical Biomechanics
- Vol. 90, 105488
Rates of neuromuscular excitation during cycling in Parkinson's disease compared to healthy young and older adults
- 1 December 2021
- Published by Elsevier in Clinical Biomechanics
- Vol. 90, 105488
Rates of neuromuscular excitation during cycling in Parkinson's disease compared to healthy young and older adults
- 1 October 2017
- Published by Elsevier in Human Movement Science
- Vol. 55, 182-188
Effect of instructions on EMG during the bench press in trained and untrained males
- 1 October 2017
- Published by Elsevier in Human Movement Science
- Vol. 55, 182-188
Effect of instructions on EMG during the bench press in trained and untrained males
- 1 March 1994
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 86 (3) , 311-323
Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine
It has previously been shown that 0.6 mg of scopolamine produces a delay in the flash visual evoked potential of young normal volunteers, while the pattern-reversal response does not change in latency. Recent work has shown that this drug differentially affects parvocellular and magnocellular systems. To investigate this effect, two studies were performed. In the first study, 0.4 mg of scopolamine was injected intramuscularly into 11 young, healthy male volunteers who had fasted overnight. The visual evoked potential was recorded to both binocular flash stimulation and monocular pattern-reversal stimulation by means of a checkerboard consisting of 56′ checks in a 28° field. Responses were recorded before administration of the drug and then 1, 2, 4 and 6 hours after administration. The scopolamine produced a slowing of the flash P2 latency of approximately 6 ms (p < 0.05) two hours after drug administration. There was no effect on the latency of the flash N2 or pattern-reversal N75 or P100. There was an increase in amplitude of the flash N2-P2 component 6 hours after drug administration and an increase in the amplitude of the N75 and P100 2, 4 and 6 hours after the drug. Further subjects were investigated with the use of topical administration of 0.125% scopolamine applied monocularly. In all studies the other eye acted as a control. The subjects were again young healthy volunteers. The visual evoked potential was recorded to both flash and pattern-reversal stimulation with a checkerboard consisting of 60′ checks counterphasing at 2 Hz within a 5° field. Results suggest that systemic scopolamine affects the tectal pathway but has no peripheral effect.
- 1 March 1994
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 86 (3) , 311-323
Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine
It has previously been shown that 0.6 mg of scopolamine produces a delay in the flash visual evoked potential of young normal volunteers, while the pattern-reversal response does not change in latency. Recent work has shown that this drug differentially affects parvocellular and magnocellular systems. To investigate this effect, two studies were performed. In the first study, 0.4 mg of scopolamine was injected intramuscularly into 11 young, healthy male volunteers who had fasted overnight. The visual evoked potential was recorded to both binocular flash stimulation and monocular pattern-reversal stimulation by means of a checkerboard consisting of 56′ checks in a 28° field. Responses were recorded before administration of the drug and then 1, 2, 4 and 6 hours after administration. The scopolamine produced a slowing of the flash P2 latency of approximately 6 ms (p < 0.05) two hours after drug administration. There was no effect on the latency of the flash N2 or pattern-reversal N75 or P100. There was an increase in amplitude of the flash N2-P2 component 6 hours after drug administration and an increase in the amplitude of the N75 and P100 2, 4 and 6 hours after the drug. Further subjects were investigated with the use of topical administration of 0.125% scopolamine applied monocularly. In all studies the other eye acted as a control. The subjects were again young healthy volunteers. The visual evoked potential was recorded to both flash and pattern-reversal stimulation with a checkerboard consisting of 60′ checks counterphasing at 2 Hz within a 5° field. Results suggest that systemic scopolamine affects the tectal pathway but has no peripheral effect.